---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-158719"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:39:53.905634+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atara resubmits tab-cel BLA to FDA for EBV+ PTLD; cash ~$22M, runway into Q1 2026

## Summary
- Atara resubmitted BLA to FDA for tabelecleucel (tab-cel) for EBV+ PTLD after CRL related to manufacturing observations.
- Pivotal ALLELE study showed 48.8% ORR (p<0.0001); no FDA-approved therapies in this setting.
- Cash, cash equivalents and short-term investments ~$22M as of June 30, 2025; cost cuts extend runway into Q1 2026.
- $40M milestone payment from Pierre Fabre due upon FDA approval; plus double-digit tiered royalties on net sales.
- Transitioning tab-cel clinical studies to Pierre Fabre; Atara maintains BLA sponsorship.

## SEC filing metadata
- accession: 0001193125-25-158719
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/0001193125-25-158719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-158719
- JSON: https://secwatch.observer/filing/0001193125-25-158719.json
- Plain text: https://secwatch.observer/filing/0001193125-25-158719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.